We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

23 hedge funds and large institutions have $1.1M invested in VYNE Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.31% more ownership

Funds ownership: 0.7% → 11.01% (+10%)

0% more capital invested

Capital invested by funds: $1.1M → $1.1M (+$3.63K)

44% less funds holding

Funds holding: 41 → 23 (-18)

60% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 15

95% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 19

Holders
23
Holders Change
-18
Holders Change %
-43.9%
% of All Funds
0.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
6
Reduced
15
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
+$99.7K
2
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$71.8K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$61.4K
4
HF
HRT Financial
New York
+$37K
5
Millennium Management
Millennium Management
New York
+$718

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$193K
2
Renaissance Technologies
Renaissance Technologies
New York
-$81.1K
3
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
-$20.2K
4
CAN
Cetera Advisor Networks
California
-$17.3K
5
Franklin Resources
Franklin Resources
California
-$14.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
BPA
26
Beacon Pointe Advisors
California
– -$11.1K -4,111 Closed
Thrivent Financial for Lutherans
27
Thrivent Financial for Lutherans
Minnesota
– -$8K -3,059 Closed
Citadel Advisors
28
Citadel Advisors
Florida
– -$8.09K -2,997 Closed
DAM
29
Deltec Asset Management
New York
– -$4.5K -1,667 Closed
Bank of New York Mellon
30
Bank of New York Mellon
New York
– -$3.99K -1,479 Closed
CL
31
CSS LLC
Illinois
– -$3.62K -1,341 Closed
TRCT
32
Tower Research Capital (TRC)
New York
– -$4.74K -1,319 -92%
TSS
33
Two Sigma Securities
New York
– -$2.83K -1,050 Closed
Jane Street
34
Jane Street
New York
– -$2.77K -1,026 Closed
LPL Financial
35
LPL Financial
California
– -$2.54K -940 Closed
SG
36
StoneX Group
New York
– -$2.08K -769 Closed
Mariner
37
Mariner
Kansas
– -$2K -694 Closed
TFA
38
Tobias Financial Advisors
Florida
– -$1.65K -611 Closed
First Manhattan
39
First Manhattan
New York
– -$383 -142 Closed
IRC
40
Investors Research Corp
Georgia
– -$23 -8 Closed
JP Morgan Chase
41
JP Morgan Chase
New York
– -$7 -2 -20%
1
2

VYNE Hedge Fund Activity: Q1 2023 in Review

23 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2023, worth a combined $1.1M — up 0.33% from $1.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VYNE and 1 opened new positions — a net loss of 18 holders — while 15 trimmed existing stakes and 6 added.

The largest buyer was DSC Advisors, adding an estimated $99.7K. The largest seller was Vanguard Group, cutting an estimated $193K.

  • 23 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2023, down from 41 in Q4 2022.
  • Funds reported $1.1M of VYNE Therapeutics stock for Q1 2023, up 0.33% quarter-over-quarter.
  • 1 fund opened new VYNE Therapeutics positions in Q1 2023 and 19 closed out, a net change of -18 holders.
  • The largest VYNE Therapeutics buyer in Q1 2023 was DSC Advisors, an estimated $99.7K added.
  • The largest VYNE Therapeutics seller in Q1 2023 was Vanguard Group, an estimated $193K sold.

Based on aggregated 13F filings for Q1 2023.